Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Urinary Retention Therapeutics Market

Urinary Retention Therapeutics Market Size

Report ID: GMI5771
Published Date: May 2023
Report Format: PDF

Download Free Sample

Urinary Retention Therapeutics Market Size

Urinary Retention Therapeutic Market size surpassed USD 3.30 Billion in 2022 and is expected to grow at a 5.8% CAGR during 2023 and 2032 driven by growing prevalence of urine incontinence (UI), and increased awareness about the advantages of early diagnosis and treatment.

To get key market trends

Download Free Sample

Urinary incontinence is a condition in which urine is lost involuntarily. It is a widespread issue that affects millions of people globally. Urinary incontinence becomes more common as people get aged. According to the Phoenix Physical Therapy, PLC., women account for 75-80% of the 25 million adult Americans who suffer from some sort of urine incontinence. The increasing prevalence of urinary incontinence in females, increasing awareness about disease treatment, and technological advancements in minimally invasive surgeries drives the growth disease treatment markets such as minimally invasive female urinary incontinence devices, urinary retention pharmaceuticals, disposable incontinence products etc.

Urinary Retention Therapeutics Market Report Attributes
Report Attribute	Details
Base Year:	2022
Urinary Retention Therapeutics Market Size in 2022:	USD 3.30 Billion
Forecast Period:	2023 to 2032
Forecast Period 2023 to 2032 CAGR:	5.8%
2032 Value Projection:	USD 5.78 Billion
Historical Data for:	2018 to 2022
No. of Pages:	110
Tables, Charts & Figures:	213
Segments covered:	Drug class, Incontinence type, Distribution channel, and Region
Growth Drivers:	Increasing prevalence of urinary incontinence (UI) Rising geriatric population across the globe Growing awareness about the benefits of early diagnosis and treatment Development of new and innovative treatment options Growing demand for home-based care
Pitfalls & Challenges:	Availability of alternate treatment options Side effects of medication

Learn more about the key segments shaping this market

Download Free Sample

Moreover, there is a rising demand for home-based treatment for people suffering with urine retention. This is owing to the fact that home-based treatment can be more convenient and less expensive than traditional hospital-based care.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for urinary retention therapeutic will record a 5.8% CAGR between 2023 to 2032.

Stress incontinence segment was 36.4% in 2022 due to high prevalence and negative impact of stress incontinence.

North America urinary retention therapeutic market surpassed of USD 889.2 million in 2022, owing to a high prevalence of urinary retention conditions in the region.

Merck KGaA, Sanofi, Pfizer Inc., GlaxoSmithKline plc., Eli Lilly, Astellas Pharma Inc., Bayer AG, Johnson & Johnson, Novartis AG, and Sun Pharmaceutical Industries Ltd.